Cue Biopharma (FRA:1UC0) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1UC0 Cue Biopharma Inc FRA:1UC0
46 GF Score
Price €22.44
GF Value €52.22
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cue Biopharma FFO?

FFO (Funds from operations) only applies to REITs.

FRA:1UC0
46GF Score
Cue Biopharma Inc FRA:1UC0
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cue Biopharma (FRA:1UC0) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of €22.44 is trading 57% below its estimated GF Value™ of €52.22. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for FRA:1UC0:

  • FFO:
  • GF Value™: €52.22 vs. price of €22.44 (57% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the FRA:1UC0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cue Biopharma Business Description

Other Exchanges CUE:USA
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
46GF Score

Get the complete analysis for FRA:1UC0

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.44
Price
€52.22
GF Value